Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05261490
Title Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Trillium Therapeutics Inc.

peritoneal carcinoma

ovary epithelial cancer

fallopian tube carcinoma


Pegylated liposomal-doxorubicin + TTI-622

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.